Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

Mohamad Bassam B SonbolBelal FirwanaZhen WangDiana Almader-DouglasMitesh J BoradIssam MakhoulRamesh K RamanathanDaniel H AhnTanios Bekaii-Saab

Published in: Cancer (2017)

Combination chemotherapy with OX or various IRI formulations appears to improve PFS compared with single-agent FP. FPIRI, but not FPOX, appears to confer an OS advantage. The combination of FP with irinotecan formulations appears to be the appropriate next line of treatment upon progression after gemcitabine-based chemotherapy regimens. Cancer 2017;123:4680-4686. © 2017 American Cancer Society.

Keyphrases

papillary thyroid
squamous cell
squamous cell carcinoma
combination therapy
replacement therapy
childhood cancer
chemotherapy induced